Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Target for Fatty Liver Disease Treatment Discovered

By Drug Discovery Trends Editor | February 3, 2016

This is an image of fatty liver. Source: CNICTwo proteins, p38 gamma and p38 delta, control the accumulation of fat in the liver, a process linked to the development of insulin resistance and diabetes, which are common outcomes of obesity. These findings are presented in an article published by researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC). The study, led by Dr. Guadalupe Sabio, shows that inhibition of these proteins with specific inhibitors has potential as a treatment for fatty liver disease. The results are published in the EMBO Journal.

Steatosis, the excessive accumulation of fat in the liver, is one of the most common diseases in developed societies, affecting almost 30 of the adult population. The disease is sometimes caused by obesity, diabetes, or excessive alcohol intake. The consequences can be serious: fatty liver can trigger cirrhosis and hepatic failure, contributes to the development of diabetes, and can lead to liver cancer. There are currently few treatment options for this disease.

Steatosis begins with an excessive accumulation in the liver of triglycerides, which stimulates an inflammatory response. Inflammation in many diseases involves contributions from p38 gamma and p38 delta, and the CNIC team discovered that the livers of obese patients express higher than normal levels of these proteins.

Using mice unable to express p38 gamma and p38 delta in neutrophils, a type of inflammatory cell, the research team showed that these two proteins control the migration of neutrophils to the liver. As the authors explain, “the arrival of these cells is necessary for the accumulation of fat in this tissue.”

Therefore, inhibition of neutrophil migration in animals lacking p38 gamma and p38 delta would be enough to protect them from the development of fatty liver, thus preventing inflammation, liver damage, and even diabetes linked to obesity.

Prevention

For Dr. Sabio, this discovery not only advances understanding of the mechamisms underlying this disease; it could also support the development of new strategies to treat or even prevent the disease. Today, the only way to test for hepatic neutrophil recruitment in obese individuals is to take a liver biopsy. With the new discovery, it may become possible to prevent neutrophil infiltration by treating patients with specific inhibitors. Dr. Sabio adds that “the finding could therefore also help in the treatment of other diseases involving hepatic neutrophil recruitment.”

The clinical aspects of the study were conducted through partnership with the team led by Dr. Miguel Marcos at the Hospital Universitario de Salamanca-IBSAL. The laboratory research was conducted by Dr. Sabio’s team at the CNIC–Drs. Bárbara González-Terán, Nuria Matesanz, and Ivanna Nikolic–and partners at the CiMUS (Center for Research in Molecular Medicine and Chronic Diseases) at the Universidad de Santiago de Compostela and at the Centro Nacional de Biotecnología in Madrid.

Source: CNIC


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE